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Cholesterol Sulfotransferase of Newborn Mouse Epidermis* 
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MATTHEW HAYNES 
Department of Dermatology, S an Francisco General Hospital and the University of California, San Francisco, California, U.S.A . 
Recent studies of the epidermis in patients with reces-
sive X-linked ichthyosis indicate that cholesterol sulfate 
is an important endogenous substrate for steroid sulfa-
tase in the stratum corneum. We report here that cho-
lesterol sulfotransferase, which converts cholesterol to 
cholesterol sulfate, is present in the lower living epider-
mis. Epidermal cytosol also sulfates phenols and some 
steroids, and such reactions may be important in defend-
ing against compounds absorbed percutaneously and in 
modulating the pharmacologic activity of topical medic-
aments. Sodium salicylate and sodium citrate inhibit the 
sulfotransferase activity noncompetitively, and inhibi-
tion of cholesterol sulfate formation may be important 
in the desquamative action of these topical "keratoly-
tics." 
The indep endent discoveries in 1976 and 1978 in Amste rdam 
a nd Los Angeles of the absence of steroid sulfatase in patients 
with recessive X- linked ich t hyosis (RXLI) focused attention 
o n sulfated stero ls and steroids in the stratum corneum [1,2). 
S ubsequently it was demonst rated that cholesterol sulfate (CS) , 
o ne substrate for steroid sulfatase, accumulates in abnormal 
a mounts in t he stratum corneum and blood of RXLI patients 
[3-5]. Furthermore, CS comprises a greater fraction of lipids 
of t h e stratum gr anulosu m t h a n of the lower epidermis, s ug-
gesting that epidermal CS might be formed in s itu rather than 
arrive by diffus ion from the blood [6]. 
W e report here studies indicating that indeed epidermis does 
co ntain an enzym e capable of transferring sulfate from 3'-
phosphoadenosine-5' -phosp hosulfate (PAPS) to cholesterol 
a nd t hat s uch preparations a lso sulfate phenols and steroids. 
Furthermore, this e n zym e is inhibited in cell - free preparations 
in vitro by sodium sa li cylate a nd sodium citrate, compounds 
t hat a re e ffective clinically in reducing stratum corneum thick -
ness. 
MATERIALS AND METHODS 
Tissues 
Newborn Swiss-Webster mice (Simonsen Labora lories, Gilroy, Cal-
ifornia ) were decapitated; the skin was removed and placed epidermis 
down on the cover of a glass Petri dish filled with ice; a nd Lhe 
subcutaneous fat was scraped away from the dermis. Whole skin was 
used as such or was separated in to epidermis and dermis afte r incuba-
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Abbreviat ions: 
CS: choleste rol sulfate 
CST: cholesterol sulfotransferase 
DHEA: dehydroepiandroste rone 
DMSO: dimethylsulfoxide 
PAPS: 3' -phosphoadenosine-5 ' -phosphosulfate 
RXLI: recessive X-linked ichthyos is 
t ion al 4 · c in medium with 0.01 M di thiot.hreilol [7). or inlo stratum 
corneum, stratum granulosum, a nd stralum basale-stratum spinosum 
by treatment with staphylococcal epidermolytic toxin [8]. Livers were 
obtained from the same newborn mice or from adult Swiss-Webster 
mice. Human keratinocytes and fibroblasts were grown under standard 
co nditions [9] and were used in early passage. 
Tissues were homogenized with a Polytron PT10 (Brinkman Instru-
ments) in TSE buffer-0.01 M Tris, pH 7.5, containing 0.15 M sucrose 
and 0.002 M EDTA at 4•c, usually at a 1:2 ratio (g wet weight:ml 
buffer). The homogenate was centrifuged at 100,000 g for 30 min at 
4 · c , and the supernatan t cytosol was used for assay of enzyme activity. 
For partial purification and removal of endogenous substrate, cyto-
sols were applied to a l.G X 4.0 ern jacketed column of Afli -Gel Blue, 
100-200 mesh (BioRad Laboratories, Richmond, California) cooled to 
4- s · c by a refri ge rated circulating water bath. The column was eluted 
at 100 ml/h successively wi t h 0.5 M NaCl in TSE and then with 1 M 
NaCl in TSE. To reduce t he NaCl conce ntration , elu ted fractions 
containing enzyme activity were dialyzed vs TSE at. 4•c for 5-18 h. 
Longer, more exhaustive dialys is caused loss of enzyme activity. Al -
though some sulfotransferase activity eluled at 0.5 M NaCl, the activity 
in Lhe 1.0 M eluate generally was more concentrated, and so t he latte r 
was used for enzyme sludies. 
Alte rnat ively, for atlempted purification, cylosol was applied to a 
jackeled 1.7 X 8.3 em column of DEAE-cellulose (Whatma n DE52) 
cooled to 4•c a nd eluted at 200 ml/ h with a linear gradient of 0- 0.3 M 
KCl in T SE buffer or to a jacketed 1.5 x 145 em column of Bio-Gel A-
1.5 m (B ioRad) cooled to 4•c a nd elu ted with TSE buffer at 10 ml/ h. 
Enzyme Assay 
Choleste rol sulfotra ns ferase (CST) activi ly was measured using mi-
nor modification s of the assay procedure of Lin and Horowitz [1 0]. 
Choleslerol, 100 11g dissolved in benzene, was placed in 13 X 100 mm 
disposable glass tubes, and Lhe solvent was evaporated to dryness at 
room temperalure . T SE, 0.050 ml , wa added, a nd Lhe cholesle rol was 
suspended by sonication. The enzyme preparation and ("5S]PAPS in 
TSE (50,000- 100,000 cpm/tube) (New Engla nd Nuclear, 1.9 Ci/ mmol , 
stated by manufacturer to be of 97% radiochemical puri ty and used 
without fur t her purification) , 0.025 eac h, were added, and the contents 
were mixed a nd incubated at 37•c without sha king. As "blanks," 
enzyme was added at the end o[ incubation . 
Substrates other than cholesterol were dissolved in dimethylsul fox-
ide (DMSO) a nd added in 0.005-ml quan t it ies. Enzyme inhibito rs were 
disso lved in TSE or DMSO and were added in 0.005 ml quantities in 
appropriate concentrations before addition of enzyme a nd ['15S]PAPS. 
Controls to which 0.005 ml of DMSO had been added we re assayed in 
each experiment. 
At the end of incubation, sulfated product and unreacted ['15S]PAPS 
were separated by pa rti tioning between orga nic a nd aqueous solu tions. 
Specif'1cally, 2.0 ml of chloroform:metha nol (2: 1 v/v) (lower phase) and 
1.0 ml of chloroform:m etha nol:water:KCl (15 ml:240 ml:235 ml:35.5 g) 
(upper phase) we re added, and t he contents were vortexed. The top 
layer was removed and discarded, and t he lower phase was extracted 
once more wilh l.O ml of the upper phase. One milliliter of the lower 
phase was placed in scintillation vials a nd allowed to evaporate over-
night to dryness at room temperature, and 10 ml of PCS (Amersham-
Searle) was added for scintillation counting. 
The identity o f [a5S ]CS synthesized enzymatically by crude whole 
skin cytosol was con!irmed by its comigration on th in -layer chroma-
tography flO] with commercially obtained CS a nd with ["H] CS. The 
latter was prepa red using the same procedure as we have used for 
preparing [3H]vitamin D:~ sulfate except that we began with 50 11 i 
[3H] choleslerol (Amersham-Searle, 5 Ci/ mm ol) instead of [3H) vitamjn 
Da (11] . 
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In some experiments, '"'S-labeled su lfaled product was separated 
from unincorporated ["5S]PAPS and ["5S]sulfate by precipitating the 
latte r with barium and zinc using Anderson a nd Weinshilboum 's mod-
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ification [1 2J of the method of Foldes and Meek [1 3]. Protein quantity 
was assayed by the method of Lowry IJ 4 j. 
RESULTS 
Sulfotr a.ns(era.se Activity 
Using the pa rtitioning assay, t he amount of [""S]CS formed 
was linearly p roportional to the time of incubation at 37·c (up 
to 4 h) and to the amount of Affi -Gel Blue-purified cytosol 
add ed. Enzyme activity was max imal between pH 7.0- 8.0. No 
CST activity was detected by barium -zinc precipitation, p,re-
sumably because ["·' S]CS was precipitated along with the [·1·'8] 
PAPS. Crude cytosol from skin or liver contained enough 
endoge nous substrate so that addit ion of cholesterol did not 
inc r ease the amount of "5S- labeled product formed. When ~y­
toso l was partially purified by column chromatography on Affi-
Gel Blue, ar'S-labeled product formed was minimal in the a.b-
sence of added substrate. Crude skin cytosol and matenal 
partially purified by Affi-Gel Blue chromatography each lost 
approximately two-th irds of their enzyme activity after 1 month 
of storage at -2o· c . . 
C rude, undiluted cytosol from whole newborn mouse skm 
sulfated cholesterol more actively than did ~ytoso l . f:om hve r 
of newborn or adu lt mice. However, t he specific actiVIty of the 
enzym e increased with dilut ion of the cytosol, presumab.ly 
becau se of dilution of endogenous inhibi tors [15] and was st1ll 
higher when enzyme was partially purified by Affi-Gel Blue 
chromatography (Table I) . 
CST activity clearly was present in crude cytoso l prepared 
from combined epidermal basal and spinous layers (7.9 pmol 
[3sS]CS formed/h incubation/ mg prote in) but was undetectable 
· n cytosol from stratum granulosum, stratum corneum, or whole 
dermis . Simila rly, crude cytosol from confluent cul tures of 
human fibrob lasts had no detectable CST activity, whereas 
cytosol f rom cultured human keratinocytes sulfated chol.esterol 
actively (5 pmol [""S]CS formed/ h incubat ion/ mg protem). 
Skin cytosol that was partially purified by Affi-Gel B lue 
chromatography sulfated not only cholesterol bu t als.o several 
steroid a nd phenolic subst rates. The 3- hydroxy ste rOids dehy-
droepiandroste rone (DHEA) and androsterone were sulfated, 
whereas the 3-keto, 17-keto ste roid androstenedione, and fl -
estradiol and corticosterone did not s~rv~ as su lfate acceptors 
when measured either by the pa rt1t10 nmg assay or by the 
barium-zinc precipitation assay . As reported by others (16] 
high concentrations of steroids inhibited their o~n sulfatwn. 
For example, addi t ion of DHEA to 10 and 100 11M fma l concen-
tration produced essentia lly equal sulfated product, but 3 mM 
DHEA resulted in 95% less sulfated product (91% and 99% 111 
two experiments!. ~igh concentration of DHEA inhibi;e~ n~t 
only its own sulfatwn but also that of cholesterol-83 % mhl-
bition at 3 mM DHEA concentration. Furthermore, ste roids 
not themselves substrates for su lfation also inhibited choles-
terol sulfation. T hus (3-estradiol, co rticoste rone, dexan~etha­
sone, and desox imetasone, all inhibited cho l este~ol sulfatwn at 
K of approximately 300-600 llM when a saturatmg concentra-ti~n of c h olesterol was present. Hydrocortisone was a somewhat 
TABLE I. CST acLivU.y" 
Newborn Adult 
Skin Liver liver 
U ndil uted'' 4.8 0.8 1.0 
Di lu ted 58 25 
Partially purified 198 181 
a Enzyme activity is exp ressed as pmol [""S]CS formed/ h incubation/ 
mg cytosol protein . All enzyme assays were performed on a single day. 
Undiluted, di lu ted, and partially purified enzymes were e11ch from a 
single preparation of mouse cytoso l. . 
b Micrograms protein/ 0. 100 ml incuba tion were 40- 110 for unddu:ed 
enzyme, 2- 4 for di lu ted enzyme, and 1..5-3 for enzyme part1ally pun fled 
by Affi-Ge l Blue chromatography. 
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FIG 1. Inhibition of sulfation of cholesterol at various co ncentra-
tio ns of [3''S]PAPS by va rious concentration of sodium salicylate: e 
=zero, .A. = 25 mM, + = 37.5 mM sodium sa licylate. 
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FIG 2. Inhibition of su lfation of DHEA at various concentrations 
of DHEA by various concentrations of sodium salicylate: e = zero, .A. 
= 25 mM , + == 37.5 mM , T == 50 mM sodium salicylate. 
less potent inhibiter wit h a K; of approximately 3 mM . By 
cont rast, addition of cholesterol in amounts that if complete ly 
dissolved would produce final concentrations as high as 2.5 mM 
(100 .ug/tube) fa iled to inhibit its own sulfat ion. Using enzyme 
partially purified by Affi-Gel Blue chromatography, t he appar-
ent]{, values were as fo llows: PAPS, 0.1 11M (Fig 1); cholesterol, 
0.2 llM ; DHEA, 12 11M (Fig 2) (2 experiments each). 
Skin enzyme pa rtially purified by Affi-Gel blue chromatog-
rap hy sulfated both p-nitrop henol and m-ni t rophenol, and the 
latter consistent ly produced more radio labe led product than 
did the former. Because approximately one-third of m-nitro-
phenol sul fate was extracted into each wash of the aqueous 
phase, t he partitioning assay gave consistent ly lower results 
than did the barium-zinc precipitation assay. However, when 
corrected for those losses, t he two assays gave similar resu lts 
for phenol sulfotransferase activity. 
Sulfotransferase activity toward choleste rol, m-ni t rophenol, 
and DHEA coeluted from Affi-Gel Blue, DEAE-cellulose, and 
Bio-Gel A-1.5 m. However , materia l t hat was chromatographed 
sequent ially on all three lost nearly a ll enzyme activity and still 
was impure, a judged by the induction of antibodies to a 
number of proteins devoid of sulfotransferase activity (not 
shown) . Such labili ty of purified enzyme has been noted by 
others [17]. 
Inhibition of Sulfotra.nsfera.se 
Sodium salicylate (2-hydroxy-benzoate) inhibi ts sulfotrans-
fe rase activity toward cholesterol, DHEA, and m-nit rophenol 
wit h a K, of approximate ly 0.015 M (Fig 3). The inhibition 
appears to be noncompetit ive with respect both to PAPS (Fig 
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F1c: a. Inhibi t ion of sulfat.ion of cholesterol by various concentra-
t ion>; of sodium sa licylate, sodium cit rate, and sodium chloride. 
1) and to DHEA (Fig 2). Addit ion of sodium salicylate a fter 
incubation fa il ed to affec t t he amount of [' lf'S] CS detected after 
t he standard aqueous methanol extraction of ['1"S]PAPS. 
We were unable chemically to sulfate sodium salicylate under 
condi t ions that lead to sulfation of vi tamin D, cholesterol, and 
DHE A [11 ], a findin g consistent with studies by others [18], 
and we found no evidence that salicylate itself was sulfa ted 
enzy matically in our preparations (by t he partit ioning or bar-
ium-zinc precipitation assays or by t hin -layer chromatogra-
phy) . 
Sodium cit rate, a neutralized a-hydroxy acid, is a weaker 
inhibito r of CST , with a K. of 0.036 M . Sodium chloride inhibits 
t his enzyme only at a considerably higher concent ration: K; 
0.200 M (Fig 3). 
DISCUSSION 
The impetus fo r t his work was the finding of elevated CS in 
the stratum corneum of patients with RXLI [3], indicating that 
CS is a major substrate fo r steroid sulfatase in the epide rmis. 
T he presence of CST in the combined basal and spinous cells 
suggests t hat CS is fo rmed locally, and we have termed the pair 
of reactions by which cholesterol is sulfated in the living 
epidermis and t hen desul fated in the stratum corneum the 
"epidermal cholesterol sul fate cycle" [19]. 
S ince excessive CS is associated with impaired desquamation 
in humans when produced endogenously in RXLI and in hair-
less mice when applied exogenously [20], we believe that it is 
reasonable to consider whether reduction of CS levels might be 
one mec hanism by which topical "keratolytic" agents might 
enhance co rneocyte shedding. Therefore we have investigated 
t he effects of such "keratolytic" agents on CST enzyme activity. 
Specifically we studied t he effect of sodium salicylate on CST 
activity because (1) others have shown that salicylamide inhib-
its phenol sulfotransferase in experimen ta l animals [21] and 
that salicylate may inhibit sulfation in humans [22], (2) sali-
cyli c acid has been used for two millenia to decrease stratum 
corneum thickness [23], and (3) it has been suggested that 
topical salicylic ac id causes shedding by decreasing corneocyte 
to corneocyte cohesion [24]. S imilarly, cit ric acid and other a-
hydroxy acids have been used topically to remove thickened 
stratum corneum for a decade [25). Al t hough it is known that 
plasma free salicylate concent rations may reach 0.005 M after 
oral ingestion of a toxic dose [26], we can find no data on the 
concentration of salicylate in the epidermis following topical 
application. It may be relevant that salicylic acid generally is 
applied in very high concentrations (e.g., a 6- 8% oint ment or 
gel or a 40% plaster) , and it is possible t hat such doses could 
produce the relatively high epidermal concent ration that would 
be needed to inhibit CST. Obviously it will be necessary to 
demonstrate directly in an in vivo model that topica l sa licylic 
acid reduces CS formation before the inhibition of CST can be 
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considered to be of pha rmacologic importance. S imilar consid-
erations hold fo r t he in vivo signi fica nce of the in vit ro inhibi-
tion of CS fo rmation by sodium citrate. In addit ion , salicylates 
are known to be inhibitors of many other enzymes, some of 
which (e.g., t hose responsible for mucopolysaccharide synt hesis 
[27,28)) also may be important in stratum corneum cohesion. 
We found that epidermis can sulfate not only cholesterol but 
also some steroids and phenols. Generally sulfation is consid-
ered to be a mechanism by which relatively lipophilic sub-
stances are converted to more water-soluble, less toxic forms. 
Sulfotransferases have been studied mostly in the liver, where 
there are several sulfot ransferases of broad and overlapping 
specificity, a situat ion t hat seems appropriate for defense 
against a variety of compounds [29). Although we were unable 
to sepa rate sulfating activit ies toward cholesterol, phenols, and 
DHEA, it is likely that more than one sulfotransferase molecule 
exists in the skin as in other t issues. A few studies have 
indicated that important sulfoconjugation occurs at t he body 
periphery in the gut and lung befo re tox ic substances reach the 
liver [30,31], and it is likely t hat epidermal sulfoconjugation 
also would be a useful mechanism of detoxification. 
Relatively little consideration has been given to the ability 
of skin to metabolize t hose fo reign compounds t hat do penetrate 
the stratum corneum. The epidermis clearly has aryl hydrocar-
bon hydroxylase activity [32], and recent ly keratinocytes iso-
lated from hairless mice were found to have several drug-
metabolizing activit ies including 7 -ethoxycoumarin 0 -deethy-
lase, UDP-glucuronosyl t ransferase, and GSH-S-t ransferase 
[33]. 
It is tempt ing to speculate that t he effectiveness and toxicity 
of topically applied medicaments might be influenced signifi -
cant ly by metabolism in t he skin. For example, t he duration of 
action of phenols applied topically as ant ipruritics might well 
be shorte ned by sulfoconjugation. By cont rast, sulfoconjugation 
can activate some carcinogens [34). Also the sulfated form of 
minoxidil may be t he vasoactive form [35], and so its effect ive-
ness after topical use might well depend on epidermal or per-
haps follicular sulfoconjugation. 
We wish to thank Dr. Peter M. Elias and his associates for providing 
the cultured human keratinocytes and !ibroblasts and t he isolated 
epidermal st rata used in t his study. 
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